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Abstract
Objective—To examine associations between lipids (HDL, LDL, total cholesterol, triglycerides, 
lipoprotein (a)) measured on average three time-points during pregnancy and neonatal 
anthropometrics.
Study Design—Stored samples from a preeclampsia trial measured as part of a case-control 
study from five US centers (1992-1995) were used. The sample included women without 
pregnancy complications (n=136), and cases of gestational diabetes (n=93), abnormal glucose 
tolerance (n=76), gestational hypertension (n=170), and preeclampsia (n=177). Linear regression 
and linear mixed-effects models estimated adjusted associations between lipids and birth weight z-
score, ponderal index, length, and head circumference.
Results—Among women without complications, cross-sectional associations between total 
cholesterol measured at different gestational ages increased ponderal index 2.23 to 2.55 kg/m3 per-
unit increase in cholesterol. HDL was inversely associated with birth length (β's=-2.21 and -2.56 
cm). For gestational hypertension, triglycerides were associated with birth weight z-score 
(β's=0.24 to 0.31). For preeclampsia, HDL was associated with lower birth weight z-scores 
(β's=-0.49 and -0.82). Women with gestational diabetes or abnormal glucose tolerance had 
inconsistent associations. Examining the level changes across pregnancy, each 0.0037 mmol/L 
increase in HDL was associated with decreased birth weight z-score (β=-0.22), length (β=-0.24 
cm), and head circumference (β=-0.24 cm) whereas each 0.028 mmol/L increase in triglycerides 
was associated with increased birth weight z-score (β=0.13) and head circumference (β=0.19 cm).
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Address correspondence to: Edwina Yeung, PhD, Division of Intramural Population Health Research, Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, 6710B Rockledge Dr., Room 3122, Bethesda, MD 20817. 
yeungedw@mail.nih.gov. Phone #(301)435-6921. 
Disclosure of Interests: The authors have no conflicts of interest to disclose.
Disclaimer: Drs. Mendola, Liu, and Yeung are employees of the federal government.
HHS Public Access
Author manuscript
J Perinatol. Author manuscript; available in PMC 2017 September 23.
Published in final edited form as:













Conclusion—Although associations varied by complications, in general, growth promoting fuels 
as total cholesterol and triglycerides were associated with increased neonatal size whereas high 
HDL was associated with smaller size. Maternal HDL that failed to decrease over pregnancy was 
associated with smaller neonate size.
Keywords
Maternal lipids; Newborn; Ponderal index; birth weight z-score; birth length; birth head 
circumference
Introduction
Inappropriate fetal growth, often assessed by birth weight, has an important effect on the 
future risk of coronary heart disease, hypertension, and type 2 diabetes.1 While the impact of 
hyperglycemia in pregnancy, particularly in overt gestational diabetes, on fetal growth is 
well documented,2-4 studies examining associations between other maternal fuels and 
newborn size, however, have been limited. The majority of the studies examined lipid 
biomarkers measured at one time point during pregnancy while restricting the study sample 
to diabetic pregnancies, non-diabetic pregnancies with positive diabetic screens, or 
uncomplicated pregnancies.5-11 Findings from these studies have been inconsistent. We 
sought to understand whether the heterogeneity in previous findings were due to having 
different timing of specimens, different case mix group of women with and without 
complications or the specific measure of neonatal size evaluated. Furthermore, studies did 
not have multiple measures from both before and after the clinical diagnosis of these 
conditions. Lipid biomarkers, if proven useful, may also be relatively easy to implement in 
clinical settings as hospital laboratories are already equipped to measure lipids for the 
purpose of cardiovascular screening in non-pregnant populations. We examined whether 
maternal circulating fuels, measured on average at three time points during pregnancy, 
influenced neonatal size stratifying by common pregnancy complications (i.e. gestational 
diabetes, abnormal glucose tolerance, gestational hypertension, preeclampsia, or no reported 




The study population was derived from the Calcium for Preeclampsia Prevention (CPEP) 
trial, a randomized double-blind clinical trial (1992-1995) conducted among 4,589 healthy 
nulliparous women with singletons pregnancies and without preexisting hypertension or 
proteinuria across 5 US centers to examine the impact of calcium supplementation on the 
incidence and severity of preeclampsia.12 Women were randomized at a gestational age 
between 13 weeks 0 days to 21 weeks 6 days as determined from the earliest obstetrical 
ultrasound.12 Details of the study have been published elsewhere.12 The trial showed no 
effect of calcium on the risk or severity of preeclampsia.13 The final sample size included 
3,667 women after excluding women who were lost to follow-up (n=283), those who had a 
pregnancy loss (n=49), had an infant with a chromosomal abnormality (n=1), or had no 
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blood collected during the baseline screening visit or misdated samples (n=589).14 We 
measured lipids as part of a nested case-control study to examine biomarkers associated with 
risk of pregnancy complications.15 Given the use of existing de-identified samples, this 
study was exempted from Institutional Review Board review and approved by the National 
Institutes of Health's Office of Human Subjects Research.
Pregnancy complications strata
The “normal” group free of pregnancy complications (n=136) consisted of a random group 
of women who were normoglycemic, normotensive, without proteinuria, and who delivered 
a term, not small for gestational age infant. The pregnancy complication strata included 
women with gestational diabetes (GDM; n=93), abnormal glucose tolerance (i.e., having an 
initial positive diabetic screen followed by a normal glucose tolerance test) (n=76), 
gestational hypertension (n=170), and preeclampsia (n=177). Women with more than one 
pregnancy complication were included in each group accordingly. Detailed definitions of 
preeclampsia and gestational hypertension diagnosis are published elsewhere.13,14,16 Briefly, 
preeclampsia was defined as pregnancy associated hypertension, a diastolic blood pressure 
≥90 mmHg on two different occasions 4 to 168 hours apart, and proteinuria, characterized as 
one of the following: a urine dipstick of at least 1+ (30 mg per deciliter) on two occasions (4 
to 168 hours apart), a urine dipstick of at least 2+ (100 mg per deciliter), a protein:creatinine 
ratio ≥0.35, or a 24-hour urine specimen with ≥300 mg of protein. Gestational hypertension 
used the same cutoffs of diastolic blood pressure with no proteinuria. Gestational diabetes 
was defined according to the American Diabetes Association 1997 criteria, with a plasma 
glucose >200 mg/dl 1-hour after 50g glucose challenge test (GCT) without an oral glucose 
tolerance test (OGTT), or a 50g GCT result >140 mg/dl at 1-hour and two abnormal values 
on the 3-hour 100-gram OGTT.17 The OGTT cutoffs were ≥95 mg/dL fasting, ≥180 mg/dL 
at 1-hour, ≥155 mg/dL at 2-hours, and ≥140 mg/dL at 3-hours. Abnormal glucose tolerance 
(AGT) was defined as those who failed the 50g GCT but had a subsequent normal OGTT.
Covariates
At enrollment, women self-reported their age, race/ethnicity (Non-Hispanic White, Non-
Hispanic Black, Hispanic or other), smoking status, education, insurance status, and marital 
status. Body mass index (BMI) was calculated based on weight measured during the 
screening visit before 21 weeks' gestation and self-reported height.
Outcomes
The baby's birth weight, length, and head circumference were abstracted from medical 
records. Ponderal index (PI) was calculated as [birth weight (g) × 100/(crown heel length 
(cm))3]. Birth weight z-score was defined according to US tables that account for race, 
parity, gestational age, and sex of the infant.18 Large for gestational age (LGA) was defined 
as birth weight above the 90th percentile for gestational age.18 Gestational age was verified 
by ultrasound data from before enrollment.
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Non-fasting maternal blood samples were taken at the baseline visit prior to randomization 
(any time before 21 weeks and 6 days of gestation) and on average twice during follow-up. 
Serum samples were frozen and stored at -70°C for 17-21 years. Low and high density 
lipoprotein (LDL, HDL), total cholesterol, triglycerides, and lipoprotein (a) (Lp(a)) were 
measured by Roche Modular P chemistry analyzer (Roche Diagnostics, Indianapolis, IN) 
with coefficients of variation <4%. At higher levels of Lp(a) (≥47 mg/dl), the coefficient of 
variation was 6.5%. In total, 1640 serum samples from 595 women (n=39 women with 1 
sample, n=123 with 2 samples, n=378 with 3 samples, n=54 with 4 samples, and n=1 with 5 
samples) were sent for measurement of lipids.
Statistical methods
We described first maternal and neonatal characteristics, represented by mean (SD) or n (%) 
as appropriate, by pregnancy complication group. We also examined the lipid biomarker 
means across gestation (<22, 22-32, 33-42 weeks) by pregnancy complication group. Linear 
regression models were used to examine if significant differences existed in the lipid 
biomarker means across the three measurement time points during pregnancy and when 
comparing women in each pregnancy complication group to women in the control group. 
Correlations between lipid measurements and maternal BMI were estimated by Pearson 
correlation coefficient. We subsequently examined associations between each maternal lipid 
biomarker and neonatal anthropometry cross-sectionally at <22 weeks, 22-32 weeks, and 
33-42 weeks using linear regression models adjusting for maternal ethnicity/race (Non-
Hispanic white, non-Hispanic black, and Hispanic or other), current smoker (yes/no), and 
BMI (continuous) stratifying by each pregnancy complication to eliminate potential biases 
in the association between maternal metabolic factors and newborn anthropometrics. Women 
with preeclampsia, for example, may have growth-restricted infants due to placental 
insufficiency rather than metabolic factors. We additionally adjusted for gestational age for 
models evaluating PI, length, and head circumference as outcomes. We also evaluated the 
odds ratios and 95% confidence intervals (CI) of being born LGA in association with 
maternal hypertriglyceridemia (triglyceride levels >75th percentile value based on all serum 
measures across gestation) cross-sectionally at <22 weeks, 22-32 weeks, and 33-42 weeks 
using logistic regression analyses and adjusting for the same above variables. Using linear 
mixed-effects models, we subsequently assessed the lipid measurements across pregnancy 
by examining how the lipid trajectory (individual slopes) is associated with the examined 
newborn anthropometrics. No adjustments were made for multiple testing but we mark in 
tables associations with Bonferroni corrected p-values of <0.01 in place of <0.05 for 
statistical significance due to evaluating 5 lipid biomarkers that may have overlapping 
pathways (0.05/5). All analyses were conducted using SAS 9.3 and R 3.1.
Results
Table 1 shows the characteristics of the mothers and their infants. On average, the women 
were 21 years old and with a BMI of 27.1 kg/m2 at the screening visit. Around 50% were 
Black, and the majority were not married (76%) and had no private insurance (90%). 
Triglycerides and Lp(a) were weakly correlated with maternal BMI (r=0.10, p<0.001; 
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r=0.08, p=0.001, respectively) while no significant correlations were detected for LDL and 
total cholesterol. Maternal BMI was inversely related to HDL-cholesterol (r=-0.12, 
p<0.001).
Mean levels of all the examined biomarkers differed significantly across pregnancy except 
for HDL and Lp(a) (Table 2). HDL was higher at the baseline measurement <22 weeks in 
comparison to the final measurement at 33-42 weeks while Lp(a) did not show any changes 
across gestation. Compared to women without pregnancy complications, women with GDM 
had lower levels of total cholesterol, HDL, and LDL but higher levels of triglycerides while 
women with gestational hypertension had lower levels of total cholesterol and LDL but 
higher levels of triglycerides. Women with preeclampsia or AGT in comparison to women 
without pregnancy complications had similar levels of all the lipid biomarkers except for 
triglycerides.
Table 3 shows only the significant associations between maternal lipid biomarkers and 
neonatal anthropometrics by pregnancy complication group at the three time point 
measurements across gestation. In general, total cholesterol, LDL, and triglycerides were 
associated with greater growth whereas HDL was associated with less growth. However, 
some variability in the associations was observed between women with different pregnancy 
complications depending on the type of lipid biomarker, timing of the measurement, and 
anthropometric measure evaluated. Specifically, among women without pregnancy 
complications, total cholesterol was consistently associated with PI at all three 
measurements across gestation; a 1 unit increase in cholesterol increased the PI by 2.23-2.55 
kg/m3 independent of maternal factors. HDL was associated with decreased length at 
baseline and near delivery. Other associations at single time points were also observed but 
no associations were detected with Lp(a).
Among women with GDM, only lipid measures taken late in pregnancy were associated 
with neonatal size. In particular, HDL was associated with a lower birth weight z-score 
(β=-1.16, 95% CI: -1.92, -0.40) while triglycerides were associated with higher birth weight 
z-score (β=0.21, 95% CI: 0.0010, 0.42). Among women with gestational hypertension, 
triglycerides were consistently associated with birth weight z-score regardless of time of 
measurement (β=0.24 to 0.31). Total cholesterol and LDL were also associated with greater 
size measures. Among women with preeclampsia, second and third HDL measurements 
were associated with decreased birth weight z-score (β=-0.49 to -0.82) and decreased PI 
(β=-1.50 to -2.56 kg/m3) while only the third measurement was associated with head 
circumference (β=-1.33 cm). Other sporadic associations were noted with LDL and Lp(a). 
Very few associations were detected between maternal lipid biomarkers and neonatal 
anthropometrics among women with AGT. Only HDL at the first measurement was 
associated with head circumference (β=1.28 cm; 95% CI: 0.10, 2.47) while HDL at the 
second measurement was associated with decreased PI (β=-3.00 kg/m3; 95% CI: -5.90, 
-0.11) (data not shown). When we examined maternal hypertriglyceridemia (triglyceride 
levels >75th percentile value; 2.69 mmol/L) in association with LGA, we found no 
significant associations in any of the pregnancy complication groups.
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Given the similarities in patterns of change for each lipid measured between women with 
different pregnancy complications (Table 2), we examined the change in lipid levels 
grouping all women but also additionally adjusting for the type of pregnancy complication. 
Examining the longitudinal lipid measurements with the neonatal anthropometric measures 
shows that a 0.0037 mmol/L increase in HDL across pregnancy was associated with 
decreased birth weight z-score (β=-0.22, 95% CI: -0.30, -0.14), length (β=-0.24 cm, 95% 
CI: -0.46, -0.015), and head circumference (β=-0.24 cm, 95% CI: -0.38, -0.11), while a 
0.028 increase in triglycerides was associated with increased birth weight z-score (β=0.13, 
95% CI: 0.034, 0.22) and head circumference (β=0.19 cm, 95% CI: 0.040, 0.34). Adjusting 
for pregnancy complications did not change any of the estimates. None of the other 
trajectories of total cholesterol, LDL, and Lp(a) were associated with neonatal 
anthropometric measures (data not shown).
Discussion
Main Findings
We examined the dynamic changes of lipid levels across gestation and the cross-sectional 
associations between maternal fuels measured on average at three time points during 
pregnancy and neonatal anthropometrics among women with uncomplicated and 
complicated pregnancies. Cross-sectional associations varied by pregnancy complication 
group and the timing of the measurement, which may be a function of whether the 
measurement was taken before or after the clinical diagnosis of the complication and sample 
sizes of each group. However, in general, total cholesterol and triglycerides levels promoted 
growth while HDL levels were associated with smaller size. Women with GDM or AGT had 
very minimal associations between maternal lipid levels and neonatal anthropometrics, 
suggesting that glucose levels or other factors may have a more dominant impact on 
newborn size. Examining the longitudinal associations between lipids and neonatal 
anthropometrics after adjusting for pregnancy complications shows smaller size with 
increasing HDL levels and a higher birth weight z-score with increasing triglycerides across 
pregnancy.
Strengths and limitations
Strengths of our current study include the different groups of pregnancy complications that 
were examined and the measurements at different time points. We also add to the previous 
literature by examining the PI instead of birth weight alone. It has been postulated that 
compared to birth weight, the PI might be a better marker of future cardiovascular health as 
it reflects different temporal patterns of fetal undernutrition.19 Our study was limited by the 
lack of fasting blood samples. However, total and HDL cholesterol levels were unlikely 
severely impacted by fasting status.20 Fasting time would not be associated with either 
neonatal anthropometry or complication status, but such random error may have reduced 
associations to the null. CPEP also recruited nulliparous women, who were young and with 
the majority being African American, which is not representative of all US pregnancies. 
BMI was also measured in early pregnancy.
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The evidence of the impact of lipid levels on newborn size among women with no pregnancy 
complications has been inconsistent with some suggestion of differences due to pre-
pregnancy BMI. One study found that triglycerides were associated with higher birth weight 
adjusted for gestational age but only among normal weight women while HDL was 
associated with inverse size but only among overweight/obese women.21 On the other hand, 
the Pregnancy Outcomes and Community Health (POUCH) study (n=1207) found that total 
cholesterol was associated with birth size in normal weight women but HDL and 
triglycerides in overweight/obese women (adjusting for pregnancy complications).9 Since 
there was inconsistent evidence and our sample size for non-complicated women was small, 
we adjusted rather than stratified by BMI among our study controls. Even so, associations 
differed slightly also by timing of measurement, and we only observed a consistent 
association between PI and total cholesterol and an inverse association between length and 
HDL. Among undernourished Indian women, total cholesterol measured at 18 and 28 weeks' 
gestation was associated with birth weight independent of maternal factors such as dietary 
intake and other maternal fuels including fasting glucose, HDL, and triglyceride.22 In a 
Norwegian study, an inverse association was observed with HDL which persisted even after 
adjusting for gestational weight gain whereas a positive association between triglycerides 
and skinfolds (but not birth weight) was found but only after excluding women diagnosed 
with GDM.23 Yet other studies have shown more consistent associations between birth 
weight or LGA and triglycerides but not with total cholesterol.24,25 These inconsistent 
associations across studies suggest that lipid measurements are unlikely to add sufficient 
evidence to inform practice with regards to fetal growth. HDL, which is not as subject to 
differences in fasting status,20 might have been a good candidate lipid biomarker but even 
this measure did not have consistent associations as reviewed above. Perhaps what is more 
important is the trajectory of HDL, which normally decreases during pregnancy. We find 
that when HDL does not decrease as it should, it may be an indicator of smaller size at birth 
as observed in our longitudinal models.
In our examination of women with hypertensive disorders, we found different results 
depending on the severity of hypertension and timing of measurement. As CPEP was a trial 
of preeclampsia, women with blood pressure >135/85 mmHg were excluded from 
participation.12 As such, lipid measures at baseline reflect values prior to clinical diagnosis 
of hypertension or preeclampsia. These associations, however, still differed from the control 
group and only among women with gestational hypertension were consistent associations 
observed between triglycerides and the birth weight z-score. While studies have noted that 
women with gestational hypertension have higher triglyceride levels than women without 
gestational hypertension,26 no previous studies to our knowledge have examined how 
maternal lipid biomarkers are associated with newborn anthropometrics among women with 
gestational hypertension. Interestingly, only women with preeclampsia showed associations 
between Lp(a) and two of the examined newborn measures including birth weight z-score 
and length. Worth noting is that one third of the women with preeclampsia delivered a 
preterm infant.
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Lipoprotein (a), a carrier of cholesterol, has been associated with increased risk of a variety 
of cardiovascular disorders.27 As preeclampsia has some features of coronary heart disease, 
several studies have addressed the role of Lp(a) in preeclampsia.28 The role of Lp(a) in 
either normal or complicated pregnancies however, has been less conclusive. Two meta-
analyses concluded that the equivocal evidence has been a result of the different methods 
used in measuring Lp(a), the sample size, study design, and ethnicity of the study 
population.28,29 To our knowledge, the Lp(a) association with neonatal anthropometrics has 
not been explored previously.
The minimal associations observed for women with GDM or AGT might be due to the 
overwhelming effects of plasma glucose.30 In a study of over 2200 mother-baby pairs (20% 
with GDM), first visit fasting plasma glucose (10-24 weeks' gestation) was associated with 
birth weight and birth length.4 In a subsequent study among over 1500 mother-baby pairs by 
the same group, first visit triglycerides were also positively associated with birth weight and 
head circumference.8 Contrary to our findings for the AGT group, two previous studies of 
nondiabetic women (n=146 and n=83) with a positive diabetic screen found associations 
between birth weight and triglyceride levels.5,6 Both studies further found that maternal 
hypertriglyceridemia, defined as triglyceride levels above the 75th percentile, was associated 
with having an LGA infant at term5,6 with one study showing hypertriglyceridemia >259 
mg/dl (OR=11.6; 95% CI: 1.1, 122) to be an independent predictor of LGA after accounting 
for other maternal factors including prepregnancy BMI and fasting plasma glucose levels.6 
The lack of association with LGA in our study might be due to sample size limitations as we 
only had 67 women with AGT measured between 22-32 weeks' gestation with only 11 
women having triglyceride levels above 259 mg/dl. Similarly, defining hypertriglyceridemia 
as the 75th cutpoint for our sample did not impact the results (data not shown). Among 
women with GDM (n=150), maternal triglycerides measured during the 3rd trimester 
correlated significantly with newborn fat mass (r=0.17, p=0.03) but not with birth weight or 
neonatal BMI.11 Additionally, maternal triglycerides at delivery remained associated with 
LGA independent of maternal BMI.11 Associations between maternal serum triglyceride 
levels measured in early pregnancy and at 24-28 weeks' gestation and birth weight ratio 
(birth weight corrected for gestational age) independent of maternal factors however, have 
been reported in other studies.31,32
Conclusion
Despite general observations that HDL was associated with reduced neonatal size while total 
cholesterol and triglycerides may be associated with larger size, our findings in combination 
with evidence from the literature suggest that lipid biomarkers are not likely to serve as 
clinically useful markers of fetal growth and are unlikely to change clinical decision making. 
The onset of pregnancy complications, especially GDM and preeclampsia, appeared to 
further deteriorate the ability of the lipid biomarkers to predict neonatal size. Pooling 
individual data across studies may serve as one way to tease apart the utility of these 
markers. All data from this study are being made available to further such investigations.
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LGA large for gestational age
OGTT oral glucose tolerance test
PI ponderal index
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Table 2
Means of lipid biomarkers across gestation by pregnancy complication group in the CPEP 
Study
Pregnancy complication group <22 weeks 22-32 weeks 33-42 weeks p-value1
Controls N=136 N=116 N=113
 Total Cholesterol mmol/L 5.18 (0.90) 6.23 (0.99) 6.64 (1.25) <0.0001
 HDL mmol/L 1.59 (0.34) 1.64 (0.34) 1.49 (0.35) 0.0079
 LDL mmol/L 3.06 (0.85) 3.91 (0.95) 4.17 (1.30) <0.0001
 Triglycerides mmol/L 1.43 (0.46) 1.99 (0.69) 2.76 (0.94) <0.0001
 Lipoprotein A μmol/L 1.45 (1.58) 1.60 (1.70) 1.65 (1.97) 0.62
Gestational diabetes mellitus N=92 N=82 N=76
 Total Cholesterol mmol/L 5.27 (1.06) 5.84 (1.1)2 6.20 (1.29)2 <0.0001
 HDL mmol/L 1.49 (0.31)2 1.48 (0.30)3 1.37 (0.33)2 0.032
 LDL mmol/L 3.06 (0.91) 3.38 (1.07)3 3.62 (1.10)2 0.002
 Triglycerides mmol/L 1.79 (0.82)3 2.70 (1.30)3 3.11 (1.26)2 <0.0001
 Lipoprotein A μmol/L 1.18 (1.26) 1.22 (1.47) 1.32 (1.51) 0.79
Abnormal glucose tolerance N=76 N=67 N=63
 Total Cholesterol mmol/L 5.29 (0.79) 6.20 (1.12) 6.47 (1.29) <0.0001
 HDL mmol/L 1.57 (0.29) 1.54 (0.36) 1.46 (0.33) 0.14
 LDL mmol/L 3.14 (0.75) 3.91 (1.12) 4.00 (1.25) <0.0001
 Triglycerides mmol/L 1.54 (0.57) 2.29 (0.80)2 2.86 (0.93) <0.0001
 Lipoprotein A μmol/L 1.33 (1.3) 1.57 (1.59) 1.42 (1.42) 0.61
Gestational hypertension N=170 N=149 N=136
 Total Cholesterol mmol/L 5.12 (0.97) 6.00 (1.09) 6.29 (1.3)2 <0.0001
 HDL mmol/L 1.56 (0.34) 1.59 (0.38) 1.46 (0.38) 0.013
 LDL mmol/L 2.98 (0.87) 3.62 (1.10)2 3.75 (1.21)2 <0.0001
 Triglycerides mmol/L 1.52 (0.66) 2.28 (1.12)2 2.96 (1.23) <0.0001
 Lipoprotein A μmol/L 1.20 (1.19) 1.37 (1.35) 1.29 (1.36) 0.51
Preeclampsia N=166 N=152 N=125
 Total Cholesterol mmol/L 5.17 (1.04) 6.10 (1.29) 6.43 (1.70) <0.0001
 HDL mmol/L 1.54 (0.32) 1.59 (0.38) 1.47 (0.36) 0.025
 LDL mmol/L 3.04 (0.89) 3.73 (1.21) 3.83 (1.49) <0.0001
 Triglycerides mmol/L 1.50 (0.65) 2.22 (0.89)2 2.93 (1.23) <0.0001
 Lipoprotein A μmol/L 1.51 (1.34) 1.75 (1.62) 1.66 (1.59) 0.37
Figures are means (SD)
p-values from linear regression models:
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1
p-value for examining if timing of collection (<22, 22-32, 33-42 weeks) is a significant predictor,
2
p-value≤0.05 for comparing women in each pregnancy complication group to women in the control group,
3
p-value≤0.001 for comparing women in each pregnancy complication group to women in the control group.
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Table 3
Associations between maternal lipid biomarkers and neonatal anthropometrics by 
pregnancy complication group at three measurements across gestation in the CPEP Study
β (95% CI)
Baseline <22 wk GA Second 22-32 wk GA Third 33-42 wks GA
Normal
Total cholesterol
 Ponderal Index, kg/m3 2.23 (0.24, 4.22) 2.36 (0.38, 4.33) 2.55 (0.87, 4.22)1
 Length, cm -0.64 (-1.19, -0.099)
HDL
 Ponderal Index, kg/m3 6.77 (1.13, 12.4)
 Length, cm -2.56 (-4.43, -0.68)1 -2.21 (-4.22, -0.19)
LDL
 Ponderal Index, kg/m3 2.05 (0.49, 3.61)
 Length, cm -0.52 (-1.02, -0.009)
Triglycerides
 Birth weight z-score 0.19 (0.004, 0.37)
Gestational diabetes
HDL
 Birth weight z-score -1.16 (-1.92, -0.40)1
Triglycerides
 Birth weight z-score 0.21 (0.001, 0.42)
Gestational hypertension
Total cholesterol
 Birth weight z-score 0.22 (0.032, 0.41)
 Head Circumference, cm 0.32 (0.033, 0.60) 0.24 (0.008, 0.47)
LDL
 Head Circumference, cm 0.35 (0.040, 0.67)
Triglycerides
 Birth weight z-score 0.31 (0.018, 0.60) 0.29 (0.11, 0.48)1 0.24 (0.066, 0.41)1
 Length, cm 0.45 (0.10, 0.80)
Preeclampsia
Total cholesterol
 Length, cm 0.38 (0.059, 0.70)
HDL
 Birth weight z-score -0.49 (-0.97, -0.003) -0.82 (-1.39, -0.25)1
 Ponderal Index, kg/m3 -1.50 (-2.86, -0.13) -2.56 (-4.08, -1.03)1
 Head Circumference, cm -1.33 (-2.29, -0.37)1
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LDL
 Birth weight z-score 0.20 (0.008, 0.39)
 Length, cm 0.40 (0.056, 0.75)
Lipoprotein A
 Birth weight z-score 0.16 (0.034, 0.30)
 Length, cm 0.30 (0.033, 0.57)
Linear regression models adjusted for race/ethnicity, BMI, smoking status, and week of gestational age of sample collection. Models examining 
Ponderal index, head circumference, and length also adjusted for gestational age of delivery.
Only significant results are reported p-value <0.05.
1
p-value <0.01
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